Zhejiang Beta Pharma Cancer Drug Shows Quicker, Cheaper Prospects
This article was originally published in PharmAsia News
Executive Summary
China's Zhejiang Beta Pharma is working on icotinib for treating non-small cell lung cancer that in some quarters is considered a harbinger of new cancer drugs that could developed quickly and cheaply in China, according to an editorial in a medical journal.